Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: atopic dermatitis

What’s New in SLE: Pathogenesis & Novel Therapies

Samantha C. Shapiro, MD  |  September 8, 2022

Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:anifrolumabbelimumabEULARPathogenesisSLEsystemic lupus erythematosus (SLE)voclosporin

Difficult-to-Treat Lupus: When & How to Use New Therapies

Samantha C. Shapiro, MD  |  July 21, 2022

Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.

Filed under:ConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:belimumabEULARHCQHydroxychloroquine (HCQ)rituximabSLEsystemic lupus erythematosus (SLE)

Case Report: Digital Ulcers & Weight Loss in a Pediatric Patient

Anusha Vuppala, MD, & Sarwat Umer, MD  |  June 13, 2021

Juvenile dermatomyositis (JDM) is a childhood form of inflammatory myopathy affecting children younger than 18 years. The diagnosis of JDM is based on characteristic clinical features of proximal muscle weakness, skin rash, elevated muscle enzymes, magnetic resonance imaging and muscle biopsy.1 Autoantibodies seen in patients with inflammatory myopathy are not only associated with particular phenotypes…

Filed under:ConditionsPediatric Conditions Tagged with:case reportinterstitial lung disease (ILD)juvenile dermatomyositisPediatric

Upadacitinib at the FDA

Michele B. Kaufman, PharmD, BCGP  |  February 28, 2019

Upadacitinib is an investigational, oral, small molecule JAK1-selective inhibitor, which recently completed phase 3 clinical trials for treating patients with moderate to severe rheumatoid arthritis (RA). In late 2018, AbbVie Inc. submitted a New Drug Application to the U.S. Food and Drug Administration, as well as a marketing authorization application to the European Medicines Agency,…

Filed under:Drug Updates Tagged with:FDARheumatoid Arthritis (RA)U.S. Food and Drug Administration (FDA)upadacitinib

When Immunodeficiency & Autoimmunity Coexist

Susan Bernstein  |  January 17, 2019

CHICAGO—Although rare, when a patient has both primary immune deficiency and autoimmune disease, the combination can lead to life-threatening complications requiring careful, long-term therapy. In When Immune Deficiency and Autoimmunity Coexist, a session at the 2018 ACR/ARHP Annual Meeting, M. Eric Gershwin, MD, the Jack and Donald Chia professor of Medicine and chief of Rheumatology,…

Filed under:ConditionsMeeting Reports Tagged with:2018 ACR/ARHP Annual Meeting

When Immunodeficiency & Autoimmunity Coexist

Susan Bernstein  |  December 18, 2018

When a patient has both primary immune deficiency and autoimmune disease, the combination can lead to life-threatening complications. Here are some insights into the challenges of diagnosing and treating this rare subset of patients…

Filed under:Uncategorized Tagged with:common variable immune deficiencyimmune deficiency polyendocrinopathy enteropathy X-linked inheritance (IPEX)immunodeficiency

FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review

Michele B. Kaufman, PharmD, BCGP  |  December 3, 2018

The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…

Filed under:Drug Updates Tagged with:dermatitisdupilumabFDAhalobetasol propionate lotionplaque psoriasisU.S. Food and Drug Administration (FDA)

Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study

Michele B. Kaufman, PharmD, BCGP  |  April 26, 2018

Initial results from an ongoing trial show that upadacitinib outperforms adalimumab in achieving ACR20 in patients with rheumatoid arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabPsoriatic ArthritisRheumatoid Arthritis (RA)upadacitinib

Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab

Mary Beth Nierengarten  |  October 17, 2017

FDA Approves Adalimumab-adbm On Aug. 29, the FDA approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab).1 Cyltezo was approved as a prefilled syringe to treat multiple chronic inflammatory diseases, including moderate to severe active RA, active psoriatic arthritis and ankylosing spondylitis, and moderate to severe plaque psoriasis. The treatment has also been approved for moderate…

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug Updates Tagged with:adalimumabAnkylosing SpondylitisApprovalsbaricitinibBimekizumabBiosimilarsdrug updateefficacyFDAHumiraplaque psoriasisPsoriasisQualityRARheumatoid arthritisrheumatologySafetyTofacitinib

Rheumatology Coding Corner Answer: New Patient Prolonged Service Without Direct Patient Contact, Part 1

From the College  |  September 19, 2017

Take the Challenge. ICD-10 Codes R76.1—Raised antibody titer L20.8—Other atopic dermatitis R20.2—Paresthesia of skin R20.1—Hypoesthesia of skin CPT Codes 99358 and 99359 Rationale The Centers for Medicare & Medicaid Services (CMS) typically does not allow separate payment for physician services that do not require face-to-face time with a patient, but as of Jan. 1, 2017,…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodingpatient carepatient visitPractice Managementrheumatologistrheumatology

  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences